未登录.png)
分享.png)
收藏Safety and short-term outcomes of lecanemab for Alzheimer’s disease in China: a multicentre studyLi, L.L.; Wang, R.Z.; Wang, Z.; Hu, H.; Xu, W.; Zhu, L.; Sun, Y.; Chen, K.L.; Chen, S.F.; He, X.Y.; et al. 利卡奈单抗治疗阿尔茨海默病在中国的安全性与短期疗效：一项多中心研究。Brain 2025, epub ahead print. [Google Scholar] [CrossRef] [PubMed]
Ling-Ling Li; Rong-Ze Wang; Zhen Wang; Hua Hu; Wei Xu; Lin Zhu; Yan Sun; Ke-Liang Chen; Shu-Fen Chen; Xiao-Yu He; Ming-Yang Yuan; Yu-Yuan Huang; Xiao-Yan Liu; Ping Liu; Qin-Yong Ye; Jie Wang; Zi-Zhao Ju; Wei Zhang; Bin Hu; Yu Guo; Xiao-Yun Cao; Yu-Xin Li; Chuan-Tao Zuo; Wei Cheng; Teng Jiang; Lan Tan; Xiao-Chun Chen; Qian-Hua Zhao; Mei Cui; Guo-Ping Peng; Jia-Wei Xin; Jin-Tai Yu; null 分享 收藏 分享 收藏 分享 收藏 Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibodyLiu, Bingyou; Zhou, Lei; Sun, Chong; Wang, Longjie; Zheng, Yongsheng; Hu, Bin; Qiao, Kai; Zhao, Chongbo; Lu, Jiahong; Lin, Jie 分享 收藏 分享 收藏 分享 收藏 Reliability and relative validity of three physical activity questionnaires in Taizhou population of China: the Taizhou Longitudinal StudyHu, B.; Lin, L. F.; Zhuang, M. Q.; Yuan, Z. Y.; Li, S. Y.; Yang, Y. J.; Lu, M.; Yu, S. Z.; Jin, L.; Ye, W. M.; Wang, X. F. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
Brain.png)
OAAI